MRC1 and cancer: Tumors with mismatch repair deficiency (MMR-d) and high microsatellite instability (MSI-H) had been validated for rendering the tumors immunogenic and increasing response to ICI therapy, but imperfect predictive biomarkers in most cancers with controversial results across different trials [53, 54].